IFNA1 and neoplasm: The continuous administration of therapeutic low-doses of IFNα thus stimulate HECs/LSECs to shape a vascular antimetastatic barrier preventing the interaction between tumor cells and endothelial cells that are known to promote the extravasation of the former cells (Glinskii et al., 2005; Mitchell and King, 2014; Wilkinson et al., 2020).